Andrew Davis

[Andrew Davis @DavisAmd]

@adamcifu The eloquence and wisdom we are gifted as clinicians...

[Andrew Davis @DavisAmd]

@adamcifu Did they have gastric cancer??

[Andrew Davis @DavisAmd]

@adamcifu Perhaps a nod to the increasing use of synthetic patient modeling (avatar patients in EMRs to allow hypothesis testing of potential interventions, like expanding remote patient monitoring). Did the patient have blue skin??

[Andrew Davis @DavisAmd]

@VPrasadMDMPH Compare your X post "Boosters do not work in people who have had COVID" to the paper's conclusion "This does not contradict the health benefit of vaccinations of very high-risk populations at any time." and 1500 deaths/wk in U.S. Loose with facts again, Vinay.

[Andrew Davis @DavisAmd]

@adamcifu @UChicagoMed @MedChiefs @UChiPritzker Come for the excellent training, stay because you’re frozen stiff! 😉

[Andrew Davis @DavisAmd]

@VPrasadMDMPH https://t.co/kPsXQBWRXP

[Andrew Davis @DavisAmd]

@adamcifu Ours too!

[Andrew Davis @DavisAmd]

@adamcifu Isn’t this called empathetic primary care? Proven interventions for definable phenotypes would empower many clinicians, and help many patients, as opposed to positing a rare new breed of specialist doctors.

[Andrew Davis @DavisAmd]

@VPrasadMDMPH Ummm. 25 yr old medical trainees take CARE of 75 yr old English professors, and cancer patients, and transplant patients. Nosocomial transmission is a thing, Vinay.

[Andrew Davis @DavisAmd]

@adamcifu @pradzsapre A vibrant expressive and flowering life of such promise...cut short. One of the hardest things to bear in medicine and in life.

[Andrew Davis @DavisAmd]

Chances are rapidly disappearing to limit Earth’s temperature rise to the globally agreed mark, but researchers say there are some positive signs of progress. https://t.co/yKAoBfjCTU

[Andrew Davis @DavisAmd]

@VPrasadMDMPH Large KP study worth considering. Prior wild-type vax had poor protection vs XBB…bivalent booster restored protection for range of COVID-19 outcomes (esp for ED, hosp admission and critical illness), both > and <65 https://t.co/qscKOi38Ke

[Andrew Davis @DavisAmd]

@adamcifu Lots of diagnostic dilemmas too - do I chase this symptom that’s probably not concerning, but might be?

[Andrew Davis @DavisAmd]

@cailinanne @VPrasadMDMPH Funny how methodological issues only get mentioned by Vinay when a study is positive. Cases here mild, almost all alpha variant, race and gender match issues, & depends on WHO case definition. Useful paper, but hardly ‘bombshell’ or ‘sledgehammer’

[Andrew Davis @DavisAmd]

@JoshWalkos https://t.co/URt4uZulPe

[Andrew Davis @DavisAmd]

@R_Hughes1 @VPrasadMDMPH @TheAtlantic 30% reduction in those over 60. ‘Worthwhile’ if not excellent, as this is the group with highest mortality.

[Andrew Davis @DavisAmd]

@JasonSalemi @CDCgov @threadreaderapp unroll

[Andrew Davis @DavisAmd]

@tomaspueyo @threadreaderapp unroll

[Andrew Davis @DavisAmd]

@EricTopol Odd how many comments focus on ‘real world’ while ignoring 500 US deaths a day. Yes efficacy tails off after 2-3 months, but if masks in crowded areas are ‘ridiculous’, how are you protecting YOUR grandparents?

[Andrew Davis @DavisAmd]

@sudha_lakshmi @EricTopol @HarvardChanSPH Well, yes. They reduce virus particle dose after exposures and thus lead to milder infections with fewer symptoms. It's not either/or. Would you rather have a severe infection or mild one during community periods of high transmission? https://t.co/ubRWE2fTej